However, the poor prognostic impact of CRLF2 overexpression is overcome by BCR-ABL1–like signature and IKZF1 deletion in the Dutch Childhood Oncology Group trials and German Cooperative ALL trials [37]. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.